04219nas a2200457   4500000000100000008004100001260001300042653003800055653002700093653002400120653001700144653003000161653001700191653001700208653003800225653001800263653003100281653003100312653001900343653003000362653001900392653001100411653001200422653002700434653001400461653002500475653003100500653004300531653004400574100001400618700001200632700002000644700001300664700001200677700001200689245026000701300000900961490000600970520277100976022001403747       2004                            d  c2004 Jan10aAcetylmuramyl-Alanyl-Isoglutamine10aAdjuvants, Immunologic10aAntigens, Bacterial10aAntigens, CD10aAntigens, Differentiation10aB7-1 Antigen10aB7-2 Antigen10aBacterial Outer Membrane Proteins10aCD28 Antigens10aCD4-Positive T-Lymphocytes10aCD8-Positive T-Lymphocytes10aCTLA-4 Antigen10aEscherichia coli Proteins10aFlow Cytometry10aHumans10aleprosy10aMembrane Glycoproteins10aMonocytes10aMycobacterium leprae10aReceptors, Antigen, T-Cell10aReceptors, Antigen, T-Cell, alpha-beta10aReceptors, Antigen, T-Cell, gamma-delta1 aSridevi K1 aNeena K1 aChitralekha K T1 aArif A K1 aTomar D1 aRao D N00aExpression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cel  a1-140 v43 a<p>In leprosy, cell-mediated immunity (CMI) is more significant than humoral response to eliminate intracellular pathogen. T cell defect is a common feature in lepromatous leprosy (LL) patients as compared to tuberculoid type (TT) patients. For efficient initiation of CD4+, T cell response requires T cell receptor (TCR) activation and costimulation provided by molecules on antigen-presenting cells (APC) and their counter receptors on T cells. In our previous study, the defective T cell function in LL patients was restored to a proliferating state with the release of TH1 type cytokines using mycobacterial antigen(s) with two immunomodulators (Murabutide (MDP-BE) and T cell epitope of Trat protein of Escherichia coli) by presenting the antigen in particulate form in vitro to PBMC derived from leprosy patients. This observation prompted us to study the expression of the costimulatory molecules (CD80, CD86, CD28, CD152), other accessory molecules (TCR alphabeta/gammadelta) and T cell lineage molecules (CD4+ and CD8+) during constitutive and activated state of peripheral blood mononuclear cells (PBMC) derived from normal and leprosy individuals using different formulations of Mycobacterium leprae total cell wall antigen (MLCWA), Trat and MDP-BE using flow cytometric analysis. An increased surface expression of CD80, CD86 and CD28 but decreased CD152 expression was observed when PBMC of normal, BT/TT (tuberculoid) and BL/LL (lepromatous) patients were stimulated in vitro with MLCWA+MDP-BE+Trat peptide using liposomal mode of antigen delivery, while opposite results were obtained with the antigen alone. Antibody inhibition study using antihuman CD80 or CD86 completely abolished the T cell lymphoproliferation, thereby reconfirming the importance of these costimulatory molecules during T cell activation/differentiation. Though the liposome-entrapped antigen formulation has no effect on expression of alphabeta/gammadelta T cell receptor, the constitutive levels of TCR gammadelta were high in lepromatous patients. Thus, TCR bearing gammadelta appears to have a negligible regulatory role in peripheral blood of leprosy patients. The percentage of cells positive for CD4+ are increased in inducible state in all the three groups, while CD8+-positive cells were decreased in LL patients, thereby reconfirming the fact that priming of CD4+ cells are necessary for producing final effector functions. Lastly, intracellular cytokine staining experiment indicated that CD4+ cells are the major producers of IFN-gamma but not NK cells. The study highlights the reversal of T cell anergy especially in lepromatous patients through the modulation of costimulatory molecule expression under the influence of Th1 cytokines, i.e., IL-2 and IFNgamma.</p>  a1567-5769